These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 15915153)

  • 41. DrugBank and its relevance to pharmacogenomics.
    Wishart DS
    Pharmacogenomics; 2008 Aug; 9(8):1155-62. PubMed ID: 18681788
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Molecular pathology and pharmacogenomics in Alzheimer's disease: polygenic-related effects of multifactorial treatments on cognition, anxiety and depression.
    Cacabelos R
    Methods Find Exp Clin Pharmacol; 2007 Jul; 29 Suppl A():1-91. PubMed ID: 17957277
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Development of a PCR-based strategy for CYP2D6 genotyping including gene multiplication of worldwide potential use.
    Dorado P; Cáceres MC; Pozo-Guisado E; Wong ML; Licinio J; Llerena A
    Biotechniques; 2005 Oct; 39(4):571-4. PubMed ID: 16235570
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Complex disease-associated pharmacogenetics: drug efficacy, drug safety, and confirmation of a pathogenetic hypothesis (Alzheimer's disease).
    Roses AD; Saunders AM; Huang Y; Strum J; Weisgraber KH; Mahley RW
    Pharmacogenomics J; 2007 Feb; 7(1):10-28. PubMed ID: 16770341
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Hypertension pharmacogenomics: current status and future directions.
    Johnson JA; Turner ST
    Curr Opin Mol Ther; 2005 Jun; 7(3):218-25. PubMed ID: 15977418
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Asthma pharmacogenomics.
    Hawkins GA; Weiss ST; Bleecker ER
    Immunol Allergy Clin North Am; 2005 Nov; 25(4):723-42. PubMed ID: 16257635
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Global pharmacogenomics: where is the research taking us?
    Olivier C; Williams-Jones B
    Glob Public Health; 2014; 9(3):312-24. PubMed ID: 24580118
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Applying pharmacogenomics to enhance the use of biomarkers for drug effect and drug safety.
    Beitelshees AL; McLeod HL
    Trends Pharmacol Sci; 2006 Sep; 27(9):498-502. PubMed ID: 16876261
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Pharmacogenomics, informatics, and individual drug therapy in psychiatry: past, present and future.
    Preskorn SH
    J Psychopharmacol; 2006 Jul; 20(4 Suppl):85-94. PubMed ID: 16785276
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Pharmacogenomics and its implications for autoimmune disease.
    Ross CJ; Katzov H; Carleton B; Hayden MR
    J Autoimmun; 2007; 28(2-3):122-8. PubMed ID: 17418528
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Implementing the U.S. FDA guidance on pharmacogenomic data submissions.
    Goodsaid F; Frueh FW
    Environ Mol Mutagen; 2007 Jun; 48(5):354-8. PubMed ID: 17567848
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Should pharmacogenomic studies be required for new drug approval?
    Relling MV; Hoffman JM
    Clin Pharmacol Ther; 2007 Mar; 81(3):425-8. PubMed ID: 17339872
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Regulatory agency consideration of pharmacogenomics.
    Pendergast MK
    Exp Biol Med (Maywood); 2008 Dec; 233(12):1498-503. PubMed ID: 18849547
    [TBL] [Abstract][Full Text] [Related]  

  • 55. What is next in pharmacogenomics? Translating it to clinical practice.
    Valdes R; Linder MW; Jortani SA
    Pharmacogenomics; 2003 Jul; 4(4):499-505. PubMed ID: 12831326
    [TBL] [Abstract][Full Text] [Related]  

  • 56. An introduction to cost-effectiveness and cost-benefit analysis of pharmacogenomics.
    Phillips KA; Veenstra D; Van Bebber S; Sakowski J
    Pharmacogenomics; 2003 May; 4(3):231-9. PubMed ID: 12718713
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Real-world clinical effectiveness, regulatory transparency and payer coverage: three ingredients for translating pharmacogenomics into clinical practice.
    Frueh FW
    Pharmacogenomics; 2010 May; 11(5):657-60. PubMed ID: 20415556
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Beyond the clinic: 'direct-to-consumer' genomic profiling services and pharmacogenomics.
    Prainsack B; Vayena E
    Pharmacogenomics; 2013 Mar; 14(4):403-12. PubMed ID: 23438887
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Pharmacogenomic biomarker information differences between drug labels in the United States and Hungary: implementation from medical practitioner view.
    Varnai R; Szabo I; Tarlos G; Szentpeteri LJ; Sik A; Balogh S; Sipeky C
    Pharmacogenomics J; 2020 Jun; 20(3):380-387. PubMed ID: 31787752
    [TBL] [Abstract][Full Text] [Related]  

  • 60. NAVAGATE: a rubric to move from pharmacogenomics science to pharmacogenomics practice.
    Roederer MW
    Pharmacogenomics; 2012 Aug; 13(11):1307-13. PubMed ID: 22920399
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.